Renaissance Capital logo

CRSP News

US IPO Weekly Recap: Two deals flounder while one soars

FRTA

Three IPOs raised $495 million this week, led by iRhythm Technologies (IRTC), which popped 53% on its first day. The other two IPOs, CRISPR Therapeutics (CRSP) and Forterra (FRTA), priced below the range and closed the week down 1% and 6%, respectively. Forterra’s 8% drop on its first day was the eighth worst...read more

CRISPR Therapeutics prices IPO at $14, below the range

CRSP

CRISPR Therapeutics, a preclinical biotech developing therapies based on CRISPR/Cas9 gene editing, raised $56 million by offering 4 million shares at $14, below the range of $15 to $17. CRISPR Therapeutics plans to list on the Nasdaq under the symbol CRSP. Citi, Piper Jaffray and Barclays acted as lead managers on the deal....read more

US IPO Week Ahead: 3 IPOs feature industrial pipes and high-growth health care

FRTA

Three IPOs are set to raise $518 million in the week ahead. LBO'd industrial pipe maker Forterra is by far the week's largest deal, while CRISPR Therapeutics will attempt to prove that gene editing is more than a pipe dream. High-growth heart monitoring company iRhythm Technologies plans to raise $75 million. A fourth deal, Full Spectrum, is still exploring its $15 million IPO on a...read more

Gene editing biotech CRISPR Therapeutics sets terms for $75 million IPO

CRSP

CRISPR Therapeutics, a preclinical biotech developing gene editing therapies with CRISPR/Cas9 technology, announced terms for its IPO on Friday. The Basel, Switzerland-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At the midpoint of the proposed range, CRISPR Therapeutics would command a fully diluted market value of...read more